Status:
UNKNOWN
IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter Ablation
Lead Sponsor:
University Hospital, Caen
Conditions:
BTKi-induced Atrial Fibrillation
Hematologic Malignancy
Eligibility:
All Genders
18-99 years
Brief Summary
Targeted anticancer drugs have completely changed the prognosis of malignancies during the past decades. Patients suffering from malignancies live longer and this allows adverse events of anticancer d...
Detailed Description
Targeted anticancer drugs have completely changed the prognosis of malignancies during the past decades. Patients suffering from malignancies live longer and this allows adverse events of anticancer d...
Eligibility Criteria
Inclusion
- every adult patient treated by BTKi for a hematological malignancy
- with a new onset recurrence of AF occurring after BTKi initiation and treated by catheter ablation
- with an available 12 months follow up after catheter ablation
Exclusion
- Patients younger than 18 years old
- Severe mitral regurgitation/stenosis or rhumatismal heart disease whatever the grade
- Permanent AF
- Patient who had AF rhythm during the first administration of BTKi
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06130709
Start Date
December 1 2023
End Date
June 1 2025
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen University Hospital
Caen, Normandy, France, 14000